Cargando…

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study

BACKGROUND: Gonadotropin-releasing hormone (GnRH) antagonists are a promising therapeutic approach for treating hormone-dependent prostate cancer. Currently, the mainstream GnRH antagonists are polypeptide agents administered through subcutaneous injection. In this study, we evaluated the safety, ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xin, Sun, Feifei, Zhang, Xiaolei, Lin, Pingping, Shen, Kai, Shen, Yu, Ma, Lingyu, Cao, Yu, Wang, Chenjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071678/ https://www.ncbi.nlm.nih.gov/pubmed/37013610 http://dx.doi.org/10.1186/s12916-023-02834-6

Ejemplares similares

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women
por: Xu, Yi, et al.
Publicado: (2022)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022)

Assessment of the Safety of Lactobacillus casei IMV B-7280 Probiotic Strain on a Mouse Model
por: L.M., Lazarenko, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

First‐in‐human trial assessing the pharmacokinetic‐pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age
por: Broksø Kyhl, Lars‐Erik, et al.
Publicado: (2021)

Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study
por: Kåss, AS, et al.
Publicado: (2014)

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2014)

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2015)

Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study
por: Chen, Qian, et al.
Publicado: (2018)

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
por: Friedrich, Christian, et al.
Publicado: (2022)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
por: Zhao, Xue, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey
por: Racz, Boglarka, et al.
Publicado: (2020)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
por: Li, Haiyan, et al.
Publicado: (2020)

Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men
por: Anderson, Richard A, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2021)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
por: Dai, Zhijie, et al.
Publicado: (2021)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013)

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nk6mm4lb3i691i3vklk6guvj8q